MOHIT KHERA to Cardiovascular Diseases
This is a "connection" page, showing publications MOHIT KHERA has written about Cardiovascular Diseases.
Connection Strength
2.648
-
Trends in blood-based metabolic and cardiovascular risk profiles in men during treatment for testosterone deficiency: a longitudinal, retrospective cohort study. J Sex Med. 2025 Sep 04; 22(9):1564-1571.
Score: 0.390
-
Testosterone replacement therapy and cardiovascular disease. Int J Impot Res. 2022 Nov; 34(7):685-690.
Score: 0.302
-
Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk. J Sex Med. 2021 01; 18(1):83-98.
Score: 0.281
-
Hypogonadism management and cardiovascular health. Postgrad Med. 2020 Dec; 132(sup4):35-41.
Score: 0.278
-
Alternatives to Testosterone Therapy: A Review. Sex Med Rev. 2018 01; 6(1):106-113.
Score: 0.227
-
Erectile dysfunction as a marker for cardiovascular disease diagnosis and intervention: a cost analysis. J Sex Med. 2015 Apr; 12(4):975-84.
Score: 0.188
-
The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med. 2013 Feb; 10(2):562-9.
Score: 0.159
-
Testosterone deficiency and treatments: common misconceptions and practical guidance for patient care. Sex Med Rev. 2025 Jul 03; 13(3):373-380.
Score: 0.096
-
Erectile dysfunction as a holistic indicator of well-being: a narrative review. Sex Med Rev. 2025 Jan 31; 13(1):11-19.
Score: 0.093
-
Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):569-580.
Score: 0.087
-
Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 07 13; 389(2):107-117.
Score: 0.083
-
Joint association of statins and testosterone replacement therapy with cardiovascular disease among older men with prostate cancer: SEER-Medicare 2007-2015. Cancer Epidemiol. 2022 08; 79:102172.
Score: 0.077
-
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 03; 245:41-50.
Score: 0.075
-
Hypogonadism: Therapeutic Risks, Benefits, and Outcomes. Med Clin North Am. 2018 Mar; 102(2):361-372.
Score: 0.057
-
Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM?2015). J Sex Med. 2016 12; 13(12):1787-1804.
Score: 0.053
-
Male hormones and men's quality of life. Curr Opin Urol. 2016 Mar; 26(2):152-7.
Score: 0.050
-
Controversies in testosterone supplementation therapy. Asian J Androl. 2015 Mar-Apr; 17(2):175-6.
Score: 0.047
-
Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015 Feb; 90(2):224-51.
Score: 0.047
-
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
Score: 0.022
-
The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk. Clin Endocrinol (Oxf). 2018 07; 89(1):3-10.
Score: 0.015
-
Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014 Jul; 11(7):1636-45.
Score: 0.011
-
Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011 May; 123(3):17-27.
Score: 0.009